[조사 보고서] 세계의 항고혈압제 시장 (2024-2030) : 약물 종류별 (이뇨제, ACE 억제제), 유형별 (1차, 2차), 투여 경로별, 유통 채널별, 지역별

■ 영문 제목 : Anti-hypertensive Drugs Market Size, Share & Trends Analysis Report By Drug Class (Diuretics, ACE Inhibitors), By Type (Primary, Secondary), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
	■ 상품코드 : GRV24JNU114 ■ 조사/발행회사 : Grand View Research ■ 발행일 : 2023년 12월 ■ 페이지수 : 180 ■ 작성언어 : 영어 ■ 보고서 형태 : PDF ■ 납품 방식 : E메일 (납기 : 3일) ■ 조사대상 지역 : 세계 ■ 산업 분야 : 의약품

■ 판매가격 / 옵션 (부가세 10% 별도)

Single User (1인 열람용)	USD5,950 ⇒환산￦8,330,000	견적의뢰/주문/질문
Multi User (5인 열람용)	USD6,950 ⇒환산￦9,730,000	견적의뢰/주문/질문
Global/corporate License (기업 열람용)	USD8,950 ⇒환산￦12,530,000	견적의뢰/구입/질문

※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.

글로벌 항고혈압제 시장의 성장과 동향
Grand View Research, Inc.사의 최신 보고서에 따르면, 세계의 항고혈압제 시장 규모는 2030년까지 306.9억 달러에 달할 것으로 예상되며, 2024년부터 2030년까지 연평균 3.91%의 성장률을 보일 것으로 전망됩니다. 고혈압 환자의 증가는 시장 성장을 촉진하는 주요 요인입니다. 또한 비만, 암, 심장병과 같은 만성질환의 증가와 신약개발 및 맞춤의료의 혁신이 항고혈압제 시장의 성장을 촉진하고 있습니다.

좋은 결과를 보여주는 강력한 파이프라인 제품의 존재는 항고혈압제 시장 수요를 촉진하는 주요 요인입니다. 예를 들어, 2023년 9월, Alnylam Pharmaceuticals, Inc.는 고혈압 치료제인 지레베실란의 임상 2상 시험에서 주요 평가 변수를 달성하고 수축기 혈압(24시간 평균)을 유의하게 감소시켰다고 발표했습니다. 지레베실란은 안지오텐신신호르몬을 표적으로 하는 RNAi 치료제로, 피하로 투여되며 미충족 수요가 높은 환자군을 대상으로 하는 것으로 기대되고 있습니다.

고혈압은 당뇨병의 흔한 합병증이기 때문에 당뇨병 유병률의 증가는 항고혈압제 시장의 성장에 박차를 가하고 있습니다. 고혈압은 당뇨병의 흔한 합병증으로 장기적으로 심장, 혈관, 신장 및 기타 장기에 손상을 줄 수 있습니다. IDF 당뇨병 아틀라스 10판 2021에 따르면, 20~79세 성인 당뇨병 환자 수는 5억 3700만 명으로 추산되며, 2030년에는 6억 4300만 명에 달할 것으로 예상되고 있습니다.

정부의 R&D 활동과 유통에 대한 자금 지원은 항고혈압제의 가격을 낮추고, 접근성을 개선하고, 경쟁을 강화함으로써 시장 성장을 촉진하는 역할을 하고 있습니다. 예를 들어, 2023년 8월 Eazymed Technologies Pvt Ltd.는 인도의 Tamil Nadu Emerging Sector Seed Fund로부터 50만 달러를 조달했습니다. 이 회사는 이 자금을 제약회사와 직접 거래하고 2~3선 도시에서 입지를 확대하는 등 공급망 내 신규 사업에 사용할 계획입니다. 이러한 노력은 항고혈압제 시장의 성장을 촉진하고 있습니다.

또한, 새로운 고혈압 치료제 승인이 증가함에 따라 제약회사들이 새롭고 효과적인 치료법 연구개발에 투자하게 되면서 주요 업체들에게 유리한 기회를 제공할 것으로 예상됩니다. 예를 들어, 2022년 5월 FDA는 타이바소 DPI(Treprostinil) 흡입 분말을 승인했는데, 타이바소 DPI는 혈관 확장제인 트레프로스틴을 폐에 직접 전달하는 건조 분말 흡입기입니다. 트레프로스티닐은 폐동맥을 확장시켜 폐의 혈압을 낮추고 운동 능력을 향상시키는 작용을 합니다.

항고혈압제 시장 보고서 하이라이트

- 약물군별로는 칼슘 길항제가 다른 항고혈압제와의 병용에 있어 본질적인 특성으로 인해 2023년 시장을 주도할 것으로 전망됩니다.

- 유형별로는 식습관, 운동 부족, 비만, 흡연, 과도한 음주와 같은 생활습관의 변화와 노인 인구의 증가로 인해 일차성 고혈압 치료제가 2023년 가장 큰 시장 점유율을 차지할 것으로 예상됩니다.

- 투여 경로별로는 경구제가 편의성, 효과, 환자 중심적 접근으로 인해 가장 큰 점유율을 차지할 것으로 예상됩니다.

- 유통 채널별로는 전 세계적으로 다양한 의료 서비스를 제공하는 병원이 증가함에 따라 병원 약국이 시장을 주도하고 있습니다.

- 북미는 민간 기업의 투자 증가, 유리한 정부 및 보험 정책, 기술 발전, 주요 지역 사업자들로 인해 37.55%의 시장 점유율을 차지하며 확고한 입지를 구축하고 있습니다.

■ 보고서 개요

1. 조사 방법 및 범위
2. 개요
3. 세계의 항고혈압제 시장 변수, 동향, 범위
4. 세계의 항고혈압제 시장 규모 : 약물 종류별 비즈니스 분석
5. 세계의 항고혈압제 시장 규모 : 유형별 비즈니스 분석
6. 세계의 항고혈압제 시장 규모 : 투여 경로별 비즈니스 분석
7. 세계의 항고혈압제 시장 규모 : 유통 채널별 비즈니스 분석
8. 세계의 항고혈압제 시장 규모 : 지역별 비즈니스 분석
9. 경쟁 현황

■ 보고서 목차

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation
1.1.1. Market Definitions
1.2. Objectives
1.2.1. Objective – 1
1.2.2. Objective – 2
1.2.3. Objective – 3
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Gvr’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.8. List Of Secondary Sources
1.9. List Of Abbreviations
1.10. List Of Primary Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Type and Drug Class Snapshot
2.3. Route of Administration and Distribution Channel Snapshot
2.4. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers
3.4.1. Increasing the Prevalence of Hypertension and High Blood Pressure
3.4.2. Growing Geriatric Population
3.4.3. Development of New and More Effective Anti-Hypertensive Drugs
3.5. Market Restraint Analysis
3.5.1. Side Effects of Anti-Hypertensive Drugs
3.5.2. Regulatory Challenges
3.6. Business Environment Analysis
3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.6.2. Porter’s Five Forces Analysis
Chapter 4. Drug Class Business Analysis
4.1. Anti-hypertensive Drugs Market: Drug Class Movement Analysis
4.2. Diuretics
4.2.1. Diuretics Market Estimates and Forecasts, 2018 – 2030 (USD Million)
4.3. ACE Inhibitors
4.3.1. ACE Inhibitors Market Estimates and Forecasts, 2018 – 2030 (USD Million)
4.4. Calcium Channel Blockers
4.4.1. Calcium Channel Blockers Market Estimates and Forecasts, 2018 – 2030 (USD Million)
4.5. Beta-adrenergic Blockers
4.5.1. Beta-adrenergic Blockers Market Estimates and Forecasts, 2018 – 2030 (USD Million)
4.6. Vasodilators
4.6.1. Vasodilators Market Estimates and Forecasts, 2018 – 2030 (USD Million)
4.7. Others
4.7.1. Others Market Estimates and Forecasts, 2018 – 2030 (USD Million)
Chapter 5. Type Business Analysis
5.1. Anti-hypertensive Drugs Market: Type Movement Analysis
5.2. Primary Hypertension
5.2.1. Primary Hypertension Market Estimates and Forecasts, 2018 – 2030 (USD Million)
5.3. Secondary Hypertension
5.3.1. Secondary Hypertension Market Estimates and Forecasts, 2018 – 2030 (USD Million)
Chapter 6. Route of Administration Business Analysis
6.1. Anti-hypertensive Drugs Market: Route of Administration Movement Analysis
6.2. Oral
6.2.1. Oral Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.3. Injectables
6.3.1. Injectables Market Estimates and Forecasts, 2018 – 2030 (USD Million)
6.4. Others
6.4.1. Others Market Estimates and Forecasts, 2018 – 2030 (USD Million)
Chapter 7. Distribution Channel Business Analysis
7.1. Anti-hypertensive Drugs Market: Route of Administration Movement Analysis
7.2. Retail Pharmacy
7.2.1. Retail Pharmacy Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.3. Hospital Pharmacy
7.3.1. Hospital Pharmacy Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.4. Online Pharmacy
7.4.1. Online Pharmacy Market Estimates and Forecasts, 2018 – 2030 (USD Million)
Chapter 8. Regional Business Analysis
8.1. Anti-hypertensive Drugs Market Share By Region, 2023 & 2030
8.2. North America
8.2.1. North America Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.2.2. U.S.
8.2.2.1. Key Country Dynamics
8.2.2.2. Target Disease Prevalence
8.2.2.3. Competitive Scenario
8.2.2.4. Regulatory Framework
8.2.2.5. Reimbursement Scenario
8.2.2.6. U.S. Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.2.3. Canada
8.2.3.1. Key Country Dynamics
8.2.3.2. Target Disease Prevalence
8.2.3.3. Competitive Scenario
8.2.3.4. Regulatory Framework
8.2.3.5. Reimbursement Scenario
8.2.3.6. Canada Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.3. Europe
8.3.1. Europe Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.3.2. Germany
8.3.2.1. Key Country Dynamics
8.3.2.2. Target Disease Prevalence
8.3.2.3. Competitive Scenario
8.3.2.4. Regulatory Framework
8.3.2.5. Reimbursement Scenario
8.3.2.6. Germany Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.3.3. UK
8.3.3.1. Key Country Dynamics
8.3.3.2. Target Disease Prevalence
8.3.3.3. Competitive Scenario
8.3.3.4. Regulatory Framework
8.3.3.5. Reimbursement Scenario
8.3.3.6. UK Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.3.4. France
8.3.4.1. Key Country Dynamics
8.3.4.2. Target Disease Prevalence
8.3.4.3. Competitive Scenario
8.3.4.4. Regulatory Framework
8.3.4.5. Reimbursement Scenario
8.3.4.6. France Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.3.5. Italy
8.3.5.1. Key Country Dynamics
8.3.5.2. Target Disease Prevalence
8.3.5.3. Competitive Scenario
8.3.5.4. Regulatory Framework
8.3.5.5. Reimbursement Scenario
8.3.5.6. Italy Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.3.6. Spain
8.3.6.1. Key Country Dynamics
8.3.6.2. Target Disease Prevalence
8.3.6.3. Competitive Scenario
8.3.6.4. Regulatory Framework
8.3.6.5. Reimbursement Scenario
8.3.6.6. Spain Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.3.7. Denmark
8.3.7.1. Key Country Dynamics
8.3.7.2. Target Disease Prevalence
8.3.7.3. Competitive Scenario
8.3.7.4. Regulatory Framework
8.3.7.5. Reimbursement Scenario
8.3.7.6. Denmark Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.3.8. Sweden
8.3.8.1. Key Country Dynamics
8.3.8.2. Target Disease Prevalence
8.3.8.3. Competitive Scenario
8.3.8.4. Regulatory Framework
8.3.8.5. Reimbursement Scenario
8.3.8.6. Sweden Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.3.9. Norway
8.3.9.1. Key Country Dynamics
8.3.9.2. Target Disease Prevalence
8.3.9.3. Competitive Scenario
8.3.9.4. Regulatory Framework
8.3.9.5. Reimbursement Scenario
8.3.9.6. Norway Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.4. Asia Pacific
8.4.1. Asia Pacific Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.4.2. Japan
8.4.2.1. Key Country Dynamics
8.4.2.2. Target Disease Prevalence
8.4.2.3. Competitive Scenario
8.4.2.4. Regulatory Framework
8.4.2.5. Reimbursement Scenario
8.4.2.6. Japan Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.4.3. China
8.4.3.1. Key Country Dynamics
8.4.3.2. Target Disease Prevalence
8.4.3.3. Competitive Scenario
8.4.3.4. Regulatory Framework
8.4.3.5. Reimbursement Scenario
8.4.3.6. China Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.4.4. India
8.4.4.1. Key Country Dynamics
8.4.4.2. Target Disease Prevalence
8.4.4.3. Competitive Scenario
8.4.4.4. Regulatory Framework
8.4.4.5. Reimbursement Scenario
8.4.4.6. India Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.4.5. South Korea
8.4.5.1. Key Country Dynamics
8.4.5.2. Target Disease Prevalence
8.4.5.3. Competitive Scenario
8.4.5.4. Regulatory Framework
8.4.5.5. Reimbursement Scenario
8.4.5.6. South Korea Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.4.6. Australia
8.4.6.1. Key Country Dynamics
8.4.6.2. Target Disease Prevalence
8.4.6.3. Competitive Scenario
8.4.6.4. Regulatory Framework
8.4.6.5. Reimbursement Scenario
8.4.6.6. Australia Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.4.7. Thailand
8.4.7.1. Key Country Dynamics
8.4.7.2. Target Disease Prevalence
8.4.7.3. Competitive Scenario
8.4.7.4. Regulatory Framework
8.4.7.5. Reimbursement Scenario
8.4.7.6. Thailand Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.5. Latin America
8.5.1. Latin America Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.5.2. Brazil
8.5.2.1. Key Country Dynamics
8.5.2.2. Target Disease Prevalence
8.5.2.3. Competitive Scenario
8.5.2.4. Regulatory Framework
8.5.2.5. Reimbursement Scenario
8.5.2.6. Brazil Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.5.3. Mexico
8.5.3.1. Key Country Dynamics
8.5.3.2. Target Disease Prevalence
8.5.3.3. Competitive Scenario
8.5.3.4. Regulatory Framework
8.5.3.5. Reimbursement Scenario
8.5.3.6. Mexico Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.5.4. Argentina
8.5.4.1. Key Country Dynamics
8.5.4.2. Target Disease Prevalence
8.5.4.3. Competitive Scenario
8.5.4.4. Regulatory Framework
8.5.4.5. Reimbursement Scenario
8.5.4.6. Argentina Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.6. MEA
8.6.1. MEA Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.6.2. South Africa
8.6.2.1. Key Country Dynamics
8.6.2.2. Target Disease Prevalence
8.6.2.3. Competitive Scenario
8.6.2.4. Regulatory Framework
8.6.2.5. Reimbursement Scenario
8.6.2.6. South Africa Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.6.3. Saudi Arabia
8.6.3.1. Key Country Dynamics
8.6.3.2. Target Disease Prevalence
8.6.3.3. Competitive Scenario
8.6.3.4. Regulatory Framework
8.6.3.5. Reimbursement Scenario
8.6.3.6. Saudi Arabia Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.6.4. UAE
8.6.4.1. Key Country Dynamics
8.6.4.2. Target Disease Prevalence
8.6.4.3. Competitive Scenario
8.6.4.4. Regulatory Framework
8.6.4.5. Reimbursement Scenario
8.6.4.6. UAE Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
8.6.5. Kuwait
8.6.5.1. Key Country Dynamics
8.6.5.2. Target Disease Prevalence
8.6.5.3. Competitive Scenario
8.6.5.4. Regulatory Framework
8.6.5.5. Reimbursement Scenario
8.6.5.6. Kuwait Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 – 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Participant’s overview
9.2. Financial performance
9.3. Participant categorization
9.3.1. Market Leaders
9.3.2. Anti-hypertensive Drugs Market Share Analysis, 2023
9.3.3. Company Profiles
9.3.3.1. Sanofi
9.3.3.1.1. Company Overview
9.3.3.1.2. Financial Performance
9.3.3.1.3. Product Benchmarking
9.3.3.1.4. Strategic Initiatives
9.3.3.2. Boehringer Ingelheim International GmbH
9.3.3.2.1. Company Overview
9.3.3.2.2. Financial Performance
9.3.3.2.3. Product Benchmarking
9.3.3.2.4. Strategic Initiatives
9.3.3.3. Novartis AG
9.3.3.3.1. Company Overview
9.3.3.3.2. Financial Performance
9.3.3.3.3. Product Benchmarking
9.3.3.3.4. Strategic Initiatives
9.3.3.4. Johnson & Johnson Services, Inc.
9.3.3.4.1. Company Overview
9.3.3.4.2. Financial Performance
9.3.3.4.3. Product Benchmarking
9.3.3.4.4. Strategic Initiatives
9.3.3.5. DAIICHI SANKYO COMPANY, LIMITED.
9.3.3.5.1. Company Overview
9.3.3.5.2. Financial Performance
9.3.3.5.3. Product Benchmarking
9.3.3.5.4. Strategic Initiatives
9.3.3.6. Merck & Co., Inc.
9.3.3.6.1. Company Overview
9.3.3.6.2. Financial Performance
9.3.3.6.3. Product Benchmarking
9.3.3.6.4. Strategic Initiatives
9.3.3.7. AstraZeneca
9.3.3.7.1. Company Overview
9.3.3.7.2. Financial Performance
9.3.3.7.3. Product Benchmarking
9.3.3.7.4. Strategic Initiatives
9.3.3.8. Pfizer Inc.
9.3.3.8.1. Company Overview
9.3.3.8.2. Financial Performance
9.3.3.8.3. Product Benchmarking
9.3.3.8.4. Strategic Initiatives
9.3.3.9. Lupin
9.3.3.9.1. Company Overview
9.3.3.9.2. Financial Performance
9.3.3.9.3. Product Benchmarking
9.3.3.9.4. Strategic Initiatives
9.3.3.10. Sun Pharmaceutical Industries Ltd.
9.3.3.10.1. Company Overview
9.3.3.10.2. Financial Performance
9.3.3.10.3. Product Benchmarking
9.3.3.10.4. Strategic Initiatives
9.3.4. Strategy Mapping
9.3.4.1. Expansion
9.3.4.2. Acquisition
9.3.4.3. Collaborations
9.3.4.4. Disease Type/Drug Class Launch
9.3.4.5. Partnerships
9.3.4.6. Others

List of Tables

Table 1 List of Abbreviations
Table 2 Global Anti-hypertensive Drugs Market, by Region, 2018 - 2030 (USD Million)
Table 3 Global Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 4 Global Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 5 Global Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 6 Global Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 7 North America Anti-hypertensive Drugs Market, by Country, 2018 - 2030 (USD Million)
Table 8 North America Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 9 North America Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 10 North America Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 11 North America Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 12 U.S. Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 13 U.S. Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 14 U.S. Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 15 U.S. Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 16 Canada Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 17 Canada Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 18 Canada Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 19 Canada Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 20 Europe Anti-hypertensive Drugs Market, by Country, 2018 - 2030 (USD Million)
Table 21 Europe Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 22 Europe Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 23 Europe Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 24 Europe Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 25 Germany Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 26 Germany Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 27 Germany Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 28 Germany Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 29 UK Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 30 UK Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 31 UK Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 32 UK Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 33 France Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 34 France Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 35 France Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 36 France Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 37 Italy Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 38 Italy Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 39 Italy Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 40 Italy Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 41 Spain Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 42 Spain Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 43 Spain Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 44 Spain Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 45 Denmark Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 46 Denmark Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 47 Denmark Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 48 Denmark Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 49 Sweden Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 50 Sweden Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 51 Sweden Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 52 Sweden Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 53 Norway Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 54 Norway Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 55 Norway Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 56 Norway Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 57 Asia Pacific Anti-hypertensive Drugs Market, by Country, 2018 - 2030 (USD Million)
Table 58 Asia Pacific Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 59 Asia Pacific Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 60 Asia Pacific Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 61 Asia Pacific Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 62 China Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 63 China Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 64 China Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 65 China Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 66 Japan Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 67 Japan Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 68 Japan Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 69 Japan Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 70 India Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 71 India Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 72 India Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 73 India Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 74 South Korea Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 75 South Korea Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 76 South Korea Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 77 South Korea Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 78 Australia Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 79 Australia Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 80 Australia Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 81 Australia Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 82 Thailand Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 83 Thailand Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 84 Thailand Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 85 Thailand Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 86 Latin America Anti-hypertensive Drugs Market, by Country, 2018 - 2030 (USD Million)
Table 87 Latin America Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 88 Latin America Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 89 Latin America Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 90 Latin America Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 91 Brazil Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 92 Brazil Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 93 Brazil Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 94 Brazil Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 95 Mexico Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 96 Mexico Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 97 Mexico Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 98 Mexico Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 99 Argentina Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 100 Argentina Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 101 Argentina Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 102 Argentina Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 103 Middle East & Africa Anti-hypertensive Drugs Market, by Country, 2018 - 2030 (USD Million)
Table 104 Middle East & Africa Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 105 Middle East & Africa Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 106 Middle East & Africa Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 107 Middle East & Africa Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 108 South Africa Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 109 South Africa Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 110 South Africa Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 111 South Africa Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 112 Saudi Arabia Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 113 Saudi Arabia Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 114 Saudi Arabia Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 115 Saudi Arabia Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 116 UAE Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 117 UAE Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 118 UAE Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 119 UAE Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 120 Kuwait Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 121 Kuwait Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
Table 122 Kuwait Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 123 Kuwait Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)

※본 조사보고서 [세계의 항고혈압제 시장 (2024-2030) : 약물 종류별 (이뇨제, ACE 억제제), 유형별 (1차, 2차), 투여 경로별, 유통 채널별, 지역별] (코드 : GRV24JNU114) 판매에 관한 면책사항을 반드시 확인하세요.

※본 조사보고서 [세계의 항고혈압제 시장 (2024-2030) : 약물 종류별 (이뇨제, ACE 억제제), 유형별 (1차, 2차), 투여 경로별, 유통 채널별, 지역별] 에 대해서 E메일 문의는 여기를 클릭하세요.

*** 아래는 관련 보고서 소개입니다 ***

세계의 약물 남용 치료 시장 (2023-2030) : 치료 종류별 (담배/니코틴/VAPE, 알코올), 최종 용도별 (재활 센터, 클리닉, 병원), 지역별
GRV23MR038 / Grand View Research / 2023년 2월 / Grand View Research사의 본 조사 보고서는 글로벌 약물 남용 치료 시장 규모가 2023년부터 2030년 사이에 CAGR 9.05% 증가하여, 2030년에는 205.1억 달러에 달할 것으로 전망하고 있습니다. 본 자료는 글로벌 약물 남용...Substance Abuse Treatment Market Growth & Trends The global substance abuse treatment market size is expected to reach USD 20.51 billion by 2030, expanding at a CAGR of 9.05% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth is attributed to the increasing...

글로벌 초음파 기기 시장 (2024-2030) : 심장학, 방사선학
GRV24JAN145 / Grand View Research / 2023년 11월 / 글로벌 초음파 기기 시장의 성장 및 동향 Grand View Research, Inc.사의 최신 보고서에 따르면, 세계의 초음파 기기 시장 규모는 2024년부터 2030년까지 연평균 4.24% 성장하여 2030년에는 130억 7천만 달러에 달할 것으로...1. 조사 방법 및 범위 2. 개요 3. 세계의 초음파 기기 시장 변수, 동향 및 범위 4. 세계의 초음파 기기 시장 규모 : 제품별 예측 및 동향 분석 5. 세계의 초음파 기기 시장 규모 : 휴대성별 예측 및 동향 분석 6. 세계의 초음파 기기 시장 규모 : 용도별 예측 및...

세계의 첨단 치료제제 (ATMP) 시장 (2023-2030) : 치료 유형별 (세포 치료, 유전자 치료, 조직 공학 제품), 지역별 (북미, 유럽, 아시아 태평양, 기타 지역)
GRV24JNU036 / Grand View Research / 2023년 12월 / 글로벌 첨단 치료제제 (ATMP) 시장의 성장 및 동향 Grand View Research, Inc.사의 최신 보고서에 따르면, 세계의 첨단 치료제제 (ATMP) 시장 규모는 2030년까지 909.8억 달러에 달할 것으로 예상되며, 예측 기간 동안...1. 조사 방법 및 범위 2. 개요 3. 세계의 첨단 치료제제 (ATMP) 시장 변수, 동향 및 범위 4. 세계의 첨단 치료제제 (ATMP) 시장 규모 : 유형별 예측 및 동향 분석 5. 세계의 첨단 치료제제 (ATMP) 시장 규모 : 지역별 예측 및 동향 분석 6. 경쟁 현황...

세계의 인비저블 치열 교정 시장 (2024-2030) : 제품별 (투명 교정기, 세라믹 교정기, 혀측 교정기), 연령별 (청소년, 성인), 치과 유형별 (일반 치과, 교정 치과), 최종 용도별, 지역별
GRV24JNU091 / Grand View Research / 2023년 12월 / 글로벌 인비저블 치열 교정 시장의 성장과 동향 Grand View Research, Inc.사의 최신 보고서에 따르면, 세계의 인비저블 치열 교정 시장 규모는 2024년부터 2030년까지 28.5%의 CAGR로 확대되어 2030년까지 339억 달러에 달할 것으로...1. 조사 방법 및 범위 2. 개요 3. 세계의 인비저블 치열 교정 시장 변수, 동향 및 범위 4. 세계의 인비저블 치열 교정 시장 규모 : 제품별 예측 및 동향 분석 5. 세계의 인비저블 치열 교정 시장 규모 : 연령별 예측 및 동향 분석 6. 세계의 인비저블 치열 교정 시장 규모...

세계의 마이크로 RNA (miRNA) 시장 (2024-2030) : 제품 및 서비스 (기기, 소모품), 용도별 (암, 전염병), 최종 용도별, 지역별
GRV24JNU059 / Grand View Research / 2023년 12월 / 글로벌 마이크로 RNA (miRNA) 시장의 성장과 동향 Grand View Research, Inc.사의 최신 보고서에 따르면, 세계의 마이크로 RNA (miRNA) 시장 규모는 2024년부터 2030년까지 12.87%의 CAGR을 기록하며 2030년까지 36.4억 달러에 달할 것으로...1. 조사 방법 및 범위 2. 요약 3. 세계의 마이크로 RNA (miRNA) 시장 변수, 동향 및 범위 4. 세계의 마이크로 RNA (miRNA) 시장 규모 : 제품별 및 서비스 예측 및 동향 분석 5. 세계의 마이크로 RNA (miRNA) 시장 규모 : 용도별 예측 및 동향 분석 6. 세계의 마이크로 RNA (miRNA)...

※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!